University of California Irvine
Welcome,         Profile    Billing    Logout  
 129 Trials 
927 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Edward J
NCT04315571: Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents

Active, not recruiting
N/A
68
US
Gore® Viatorr® Endoprosthesis with controlled expansion, TIPS, Large Volume Paracentesis with albumin infusion, LVP with albumin infusion
University of California, Los Angeles, W.L.Gore & Associates
Hypertension, Portal, Ascites
01/26
01/26
DOORwaY90, NCT04736121: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

Active, not recruiting
N/A
100
US
Resin microspheres containing yttrium-90 (Y-90)
Sirtex Medical, Bright Research Partners
Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
10/25
12/26
O'Brien, Susan M
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
ELM-1, NCT02290951: Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Jul 2023 - Dec 2023: Submission in US for r/r/ follicular lymphoma
Jan 2023 - Dec 2023: Approval for blood cancer
Checkmark Presentation of ELM-1 and ELM-2 data from trial for DLBCL at ASH 2022
Dec 2022 - Dec 2022: Presentation of ELM-1 and ELM-2 data from trial for DLBCL at ASH 2022
Checkmark FDA lifts partial clinical hold on study of odronextamab
More
Active, not recruiting
1
200
Europe, US, RoW
Odronextamab multiple dose levels, REGN1979
Regeneron Pharmaceuticals
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
09/25
09/25
Hameed, Afshan B
NCT04861103: Anticoagulation Profile in Pregnant Women Treated with Three Times a Day of Low Molecular Weight Heparin (LMWH)

Recruiting
4
12
US
Lovenox
University of California, Irvine
Pregnancy, High Risk, Anticoagulants
12/25
07/26
REBIRTH, NCT05180773: Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Recruiting
4
250
US
Bromocriptine, Parlodel, Cycloset, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Xarelto, Second Placebo
Dennis M. McNamara, MD, MS, National Heart, Lung, and Blood Institute (NHLBI)
Peripartum Cardiomyopathy, Postpartum
06/26
12/28
Tuscano, Joseph
EVOLVE CLL/SLL, NCT04269902: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), Study

Recruiting
3
247
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA 101, GA-101, GA101, Gazyva, huMAB(CD20), R 7159, R-7159, R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/28
10/28
NCT01811368: Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
2
20
US
rituximab, IDEC-C2B8, Mabthera, Rituxan, ibritumomab tiuxetan, Zevalin, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, total nodal irradiation, TLI, total lymphoid irradiation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell, allogeneic hematopoietic stem cell transplantation, cyclosporine, cyclosporin, cyclosporin A, CYSP, Sandimmune, mycophenolate mofetil, Cellcept, MMF
Joseph Tuscano, Spectrum Pharmaceuticals, Inc
Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
04/23
12/23
NCT04450173: Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Recruiting
2
40
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Joseph Tuscano, National Cancer Institute (NCI), Pharmacyclics LLC., Genentech, Inc.
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
10/24
04/25
NCT04587687: Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Recruiting
2
23
US
Bendamustine Hydrochloride, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35
Joseph Tuscano, National Cancer Institute (NCI), Seagen Inc.
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
12/24
05/25
NCT00848328: Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
2
30
US
Rituximab, Rituxan, MabThera, Lenalidomide, REVLIMID
University of California, Davis, Celgene
Lymphoma
04/24
12/24
NCT01316523: Lenalidomide and Rituximab in Subjects with Previously Untreated Indolent Non-Hodgkin's Lymphoma

Completed
2
30
US
Rituximab, Rituxan, Lenalidomide, Revlimid
University of California, Davis, Celgene
Non Hodgkin's Lymphoma
09/23
04/24
NCT05600686: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Recruiting
2
24
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Loncastuximab Tesirine, ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Loncastuximab Tesirine-lpyl, Zynlonta, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine, Leurocristine, VCR, Vincrystine
Joseph Tuscano, National Cancer Institute (NCI), ADC Therapeutics S.A.
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
02/26
02/28
NCT05256641: Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Recruiting
1/2
24
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence
Jonsson Comprehensive Cancer Center, AstraZeneca
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Secondary Central Nervous System Lymphoma
10/25
10/26
NCT02542657: Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

Active, not recruiting
1/2
30
US
Clarithromycin, Biaxin, Dexamethasone, Decadron, Ixazomib Citrate, MLN9708, Pomalidomide, Pomalyst
Joseph Tuscano, Takeda, Celgene
Myeloma
08/25
12/25
MPCT-012L, NCT05826535: Study of IMPT-314 in R/R Aggressive B-cell NHL

Recruiting
1/2
150
US
IMPT-314
ImmPACT Bio
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
06/25
12/29
NCT02568553: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Active, not recruiting
1
44
US
Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid
National Cancer Institute (NCI)
Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mediastinal Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Gray-Zone Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Mediastinal Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
06/25
06/25
ETCTN 10500, NCT05627245: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Suspended
1
64
US
Belinostat, Beleodaq, PXD 101, PXD-101, PXD101, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Positron Emission Tomography and Computed Tomography Scan, PET-CT Scan, PET/CT SCAN, Positron Emission Tomography/Computed Tomography, Tazemetostat, E 7438, E-7438, E7438, EPZ 6438, EPZ-6438, EPZ6438
National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
03/25
03/25
NCT04578600: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Active, not recruiting
1
8
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Oral Azacitidine, CC-486
Joseph Tuscano, National Cancer Institute (NCI), Celgene
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mucosa-Associated Lymphoid Tissue Lymphoma, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
12/24
07/25
NCT04629729: FT819 in Subjects With B-cell Malignancies

Active, not recruiting
1
54
US
FT819, Cyclophosphamide, Fludarabine, Fludara, IL-2, Interleukin-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
09/24
09/39
NCT06015880: Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
1
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, FCU-2711, FCU2711, polatuzumab vedotin-piiq, Polivy, RG 7596, RG-7596, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
06/26
06/26
NCT05967533: The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors

Recruiting
1
100
US
Fermented Wheat Germ Extract, Avemar, FWGE
University of California, Davis, National Cancer Institute (NCI)
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
06/25
12/25
NCT05272384: Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Recruiting
1
27
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma
06/27
06/27
Kimonis, Virginia
NCT01166854: Characterization of Familial Myopathy and Paget Disease of Bone

Recruiting
N/A
25
US
Diffuse Optical Spectroscopy
University of California, Irvine, Beckman Laser Institute University of California Irvine
Muscle Disorder, Bone Disorder
06/22
06/22
NCT04552691: Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

Approved for marketing
N/A
US
Pegunigalsidase Alfa
Chiesi Farmaceutici S.p.A., Chiesi USA, Inc.
Fabry Disease
 
 
NCT01353430: Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)

Recruiting
N/A
50
US
University of California, Irvine
Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia, Paget Disease of Bone, Frontotemporal Dementia, Myopathy
12/25
12/26
Kalantar-Zadeh, Kamyar
NCT03191188: A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients

Recruiting
N/A
96
US
Levothyroxine Sodium, Placebo Oral Tablet
University of California, Irvine, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Thyroid Disease, Kidney Diseases, Chronic
07/21
07/21
THYROID-HD, NCT03977207: A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients

Recruiting
N/A
336
US
Levothyroxine Sodium, Placebos
University of California, Irvine, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Thyroid; Functional Disturbance, Hypothyroidism, Hemodialysis
04/25
04/25
PLAFOND, NCT05514184: Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease

Enrolling by invitation
N/A
120
US
PLAFOND diet, Plant-dominant low protein (PLADO) diet in the form of PLAFOND diet meal plans
University of California, Irvine, VA Long Beach Healthcare System
Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5, Diabetes Mellitus, Diabetic Kidney Disease
03/26
09/26
INCHVETS, NCT05465044: Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)

Recruiting
N/A
252
US
Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule, Thrice-Weekly Hemodialysis
VA Office of Research and Development
Chronic Kidney Disease (CKD) Stage 5, Kidney Dysfunction Requiring Dialysis (KDRD), Dialysis Dependency
09/27
09/27
Clayman, Ralph
NCT06335537: Impact of Sodium Bicarbonate on 24-hour Urine Parameters in Hypocitriuric and Uric Acid Stone Formers

Not yet recruiting
1
100
US
Potassium citrate, Urocit-K, Sodium bicarbonate, Baking Soda
University of California, Irvine
Uric Acid Stones
07/26
07/26
Lane, Felicia
NCT05308979: Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

Completed
4
118
US
OnabotulinumtoxinA 100 UNT [Botox]
University of California, Irvine, Kaiser Permanente, St. Joseph Hospital of Orange
Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, Urge, Urge Incontinence, Urinary Urgency, Urinary Frequency
12/23
03/24
ARTISAN-SNM, NCT03327948: Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt

Completed
N/A
129
Europe, US
Axonics Sacral Neuromodulation System (SNM) System
Axonics, Inc.
Urinary Incontinence, Urge
01/19
06/20
NCT03808974: An Educational Video to Improve Patient Comprehension of Midurethral Sling

Completed
N/A
38
US
Educational video, Educational leaflet
Felicia Lane, Kaiser Permanente
Stress Urinary Incontinence, Knowledge, Attitudes, Practice
12/20
10/21
OASIS, NCT03596671: BlueWind RENOVA iStim™ System for the Treatment of OAB

Recruiting
N/A
200
Europe, US
RENOVA iStim™ System
BlueWind Medical
Treatment of Patients Suffering From Overactive Bladder (OAB)
10/22
01/25
OCTRCT, NCT06691178: Vaginal Changes After CO2 Laser

Recruiting
N/A
50
US
Optical coherence tomography (OCT)
University of California, Irvine, Alma Lasers, National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Genitourinary Syndrome of Menopause
05/27
07/27
NCT04737616: Continuous Monitoring and Management of Vaginal Health Via Multifunctional OCT/OCTA/OCE Endoscopy

Recruiting
N/A
90
US
CO2 laser, OCT
University of California, Irvine, National Institutes of Health (NIH)
Genitourinary Syndrome of Menopause
07/26
07/26
NCT02577302: CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

Recruiting
N/A
200
US
CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
Uro Medical Corporation
Urinary Incontinence, Urge
10/25
10/25
Bota, Daniela
NCT01903330: ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Checkmark Interim results in combination with ERC1671/GM CSF/cyclophosphamide for recurrent glioblastoma
Aug 2020 - Aug 2020: Interim results in combination with ERC1671/GM CSF/cyclophosphamide for recurrent glioblastoma
Active, not recruiting
2
84
US
ERC1671, Gliovac, GM-CSF, Leukine®, sargramostim, Cyclophosphamide, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar, Avastin, MVASI, bevacizumab-awwb, bevacizumab-bvzr, ZIRABEV
Epitopoietic Research Corporation, University of California, Irvine
Glioblastoma, Gliosarcoma
03/23
03/23
NCT03450850: Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma

Active, not recruiting
2
34
US
NOVOTTF-200A
Daniela A. Bota, NovoCure Ltd.
Astrocytoma, Grade III
09/23
09/24
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
SWOG S1609, NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Checkmark From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Checkmark From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Checkmark In combination with yervoy in aggressive neuroendocrine tumors
More
Active, not recruiting
2
818
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
05/26
05/26
NCT03935685: Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ

Active, not recruiting
2
120
US
Mirtazapine (Remeron)
University of California, Irvine
Glioma of Brain
12/24
12/24
NCT03173950: Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Active, not recruiting
2
108
US
Nivolumab
National Cancer Institute (NCI)
Medulloblastoma, Ependymoma, Pineal Region Tumors, Choroid Plexus Tumors, Atypical/Malignant Meningioma
07/25
07/26
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
NCT04520139: Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

Not yet recruiting
1/2
102
NA
N-Acetyl-Cysteine, NAC Sustain, NAC, Placebo
University of California, Irvine, Jarrow Formulas Inc
Ovarian Cancer, Cognitive Impairment
12/25
12/26
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT04190628: Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Terminated
1
53
US
ABM-1310, ABM1310, Cobimetinib, Cotellic®
ABM Therapeutics Corporation
Advanced Solid Tumor, BRAF V600 Mutation
04/24
04/24
DCVax-L EAP, NCT02146066: Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221

Available
N/A
US
DCVax-L
Northwest Biotherapeutics
GBM, Glioblastoma Multiforme
 
 
Lee, Richard K
NCT03824119: Postpartum NSAIDS and Maternal Hypertension

Recruiting
4
200
US
Ibuprofen 600 mg, Standard Postpartum Care, Standard Postpartum Care without NSAIDs
University of Southern California
Preeclampsia, Gestational Hypertension, Superimposed Preeclampsia, Chronic Hypertension in Obstetric Context
12/22
12/22
NRG-BN003, NCT03180268: Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Recruiting
3
148
Canada, Japan, US, RoW
Clinical Observation, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
NRG Oncology, National Cancer Institute (NCI)
Grade II Meningioma, Intracranial Meningioma
06/27
08/27
NRG-HN005, NCT03952585: De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Active, not recruiting
2/3
384
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Image Guided Radiation Therapy, IGRT, image-guided radiation therapy, Image-Guided Radiotherapy, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI), NRG Oncology
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
03/24
12/25
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
NCT04824937: Telaglenastat + Talazoparib In Prostate Cancer

Not yet recruiting
2
30
US
Telaglenastat, CB 839, Talazoparib, Taken orally
Massachusetts General Hospital, Calithera Biosciences, Inc, Pfizer, Prostate Cancer Foundation
Prostate Cancer Metastatic
12/21
12/21
I-SPY_COVID, NCT04488081: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Recruiting
2
1500
US
Remdesivir, GS-5734, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Firazyr, Apremilast, Otezla, dornase alfa, Pulmozyme, Celecoxib, celebrex, Famotidine, Pepcid, IC14, Aviptadil, Zyesami, narsoplimab, OMS721, Cyproheptadine, periactin, Cyclosporine, CsA
QuantumLeap Healthcare Collaborative, University of California, San Francisco, University of Pennsylvania, Emory University, University of Alabama at Birmingham, University of Colorado, Denver, University of Southern California, Yale University, Wake Forest University Health Sciences, Sanford Health, Long Beach Memorial Medical Center, Georgetown University, University of California, Davis, Hoag Memorial Hospital Presbyterian, Main Line Health, DHR Health Institute for Research and Development, University of California, Irvine, Corewell Health, Kaiser Permanente, University of Michigan, West Virginia University, University of Miami, University Hospitals Cleveland Medical Center, Virtua Health, M.D. Anderson Cancer Center
COVID-19
07/28
07/30
KEYNOTE B36, NCT04892472: EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
2
100
US
NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg
NovoCure GmbH, Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
07/24
12/26
NCT06041789: Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

Recruiting
2
45
US
Donepezil, Placebo
Duke University, National Institute on Aging (NIA)
Osteoporosis
06/25
06/25
NCT06731894: Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Not yet recruiting
2
120
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cannabidiol, CBD, CBD Oil, Epidiolex, GWP42003-P, Dronabinol, (-)-.DELTA.9-Tetrahydrocannabinol, Abbott 40566, Delta(9)-Tetrahydrocannibinol, Delta-9-Tetrahydrocannabinol, Delta-9-THC, Delta9-THC, Marinol, SP 104, SP-104, SYNDROS, Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol, Tetrahydrocannabinol, THC, Placebo Administration, Survey Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
10/26
10/26
NCT04014205: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Active, not recruiting
1/2
81
Europe, US, RoW
Orelabrutinib (ICP-022)
Beijing InnoCare Pharma Tech Co., Ltd.
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
12/23
01/25
CELLO-1, NCT04179864 / 2019-003649-14: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Checkmark Data from CELLO-1 trial for CRPC at SUO 2022
Dec 2022 - Dec 2022: Data from CELLO-1 trial for CRPC at SUO 2022
Checkmark Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Sep 2021 - Sep 2021: Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Terminated
1/2
102
Europe, US
Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi
Epizyme, Inc.
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
11/24
11/24
KEYNOTE-E58, NCT04041310: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Active, not recruiting
1/2
115
Europe, Canada, US
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab
Nouscom SRL, Merck Sharp & Dohme LLC
Solid Tumor, Adult
04/25
11/26
NCT04524962: Study of Descartes-30 in Acute Respiratory Distress Syndrome

Terminated
1
12
US
Descartes 30
Cartesian Therapeutics, National Heart, Lung, and Blood Institute (NHLBI)
Acute Respiratory Distress Syndrome, Covid19
09/22
09/23
NCT05672342: Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Withdrawn
1
120
US
Cannabidiol, CBD, CBD Oil, Epidiolex, GWP42003-P, Delta-8-Tetrahydrocannabinol, .DELTA.8-TETRAHYDROCANNABINOL, delta-8-THC, Placebo Administration, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
10/25
10/25
LIBRA, NCT04270799: Lung Nodule Imaging Biobank for Radiomics and AI Research

Recruiting
N/A
1000
Europe
Machine Learning Classification
Royal Marsden NHS Foundation Trust, RM Partners West London Cancer Alliance, Royal Brompton & Harefield NHS Foundation Trust, University College London Hospitals, Imperial College Healthcare NHS Trust, Lewisham and Greenwich NHS Trust, King's College Hospital NHS Trust, Epsom and St Helier University Hospitals NHS Trust, Institute of Cancer Research, United Kingdom, Guy's and St Thomas' NHS Foundation Trust, UCLH Biomedical Research Centre
Lung Cancer, Pulmonary Nodule, Multiple, Pulmonary Nodule, Solitary, Lung Neoplasms
08/21
08/21
NCT01961843: Abiraterone Acetate for Castrate Resistant Prostate Cancer

Active, not recruiting
N/A
40
US
Abiraterone, Abiraterone acetate, Zytiga, Prednisone
Massachusetts General Hospital
Prostate Cancer
06/24
12/24
NCT01961713: Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

Recruiting
N/A
200
US
Massachusetts General Hospital, Prostate Cancer Foundation Clinical Research Consortium
Prostate Cancer
12/25
12/25
NCT02862158: Frequency Doubling Technology (FDT) Mobile Visual Field Testing

Recruiting
N/A
500
US
FDT visual field, Standard HVF
University of Miami
Glaucoma
11/22
11/22
AI-SONAR, NCT05375591: AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer

Recruiting
N/A
1000
Europe
Non-Interventional Study
Royal Marsden NHS Foundation Trust, Institute of Cancer Research, United Kingdom, National Institute for Health Research, United Kingdom, Royal Brompton & Harefield NHS Foundation Trust, Royal Marsden Partners Cancer Alliance, Imperial College London, Oxford University Hospitals NHS Trust, National Heart and Lung Institute
Indeterminate Pulmonary Nodules, Lung Metastases, Second Primary Cancer, Lung Cancer
11/22
11/26
NCT04957433: 'Lung Health Check' Biomarker Study

Recruiting
N/A
1000
Europe
Blood Specimen, Sputum Specimen
Royal Marsden NHS Foundation Trust, Royal Brompton & Harefield NHS Foundation Trust, Imperial College London, Royal Marsden Partners Cancer Alliance
Lung Cancer, Cancer
12/23
12/23
SCOOT, NCT05368298: Sample Collection for DART

Recruiting
N/A
5000
Europe
University of Oxford, Innovate UK, Optellum, National Institute for Health Research, United Kingdom, Cancer Research UK, GE Healthcare, RNA Guardian, Roche Diagnostics GmbH
Lung Cancer
02/25
02/25
PILLCAM, NCT06712095: Video Capsule Examination in Patients With Lynch Syndrome

Recruiting
N/A
25
Europe
Video capsule investigation, Colonoscopy
Royal Marsden NHS Foundation Trust, King's College London
Lynch Syndrome, Li Fraumeni Syndrome, PTEN Hamartoma Syndrome, FAP, MUTYH Biallelic Mutation, STK11 Mutation, CDH1 Gene Mutation, CHEK2 Gene Mutation, BMPR1A Gene Mutation, SMAD4 Gene Mutation
10/25
10/25
DOLCE, NCT05389774: Determining the Impact of Optellum's Lung Cancer Prediction Solution

Recruiting
N/A
2000
Europe
Nottingham University Hospitals NHS Trust, Optellum Ltd.
AI (Artificial Intelligence), Pulmonary Nodule, Solitary, Pulmonary Nodule, Multiple, Lung Cancer
01/25
01/25
NCT06500377: Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer Survivors

Recruiting
N/A
44
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Meditation Therapy, Meditation, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
06/26
06/26
NCT03615794: A Study of Pregnant and Postpartum Women With and Without Mood Disorders

Active, not recruiting
N/A
400
US
Johns Hopkins University, University of Virginia
Bipolar Disorder, Major Depressive Disorder, Postpartum Depression, Postpartum Psychosis
01/24
12/25
NCT06581211: Aromatherapy Oil Associated for Managing Anxiety and Pain During Bone Marrow Biopsy Procedures

Recruiting
N/A
45
US
Aromatherapy and Essential Oils, Aromatherapy, Electronic Health Record Review, Jojoba Oil, Lavender Oil, Common Lavender Oil, English Lavender Oil, Lavandula officinalis Flowering Top Oil, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
12/28
12/28
NCT05876676: RDC Biomarker Study

Not yet recruiting
N/A
1000
NA
Royal Marsden NHS Foundation Trust
Cancer
04/25
04/26
NIMBLE, NCT05432739: Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study

Recruiting
N/A
500
Europe
Royal Marsden NHS Foundation Trust, Royal Brompton & Harefield NHS Foundation Trust, Royal Marsden Partners West London Cancer Alliance, Imperial College London, University College London Hospitals, Lewisham and Greenwich NHS Trust, Guy's and St Thomas' NHS Foundation Trust, Epsom and St Helier University Hospitals NHS Trust, King's College Hospital NHS Trust, University College London (UCL) Cancer Institute, Institute of Cancer Research, United Kingdom, Francis Crick Institute, Royal Sussex County Hospital
Lung Cancer
01/26
01/31
Ciurea, Stefan
NCT02441803: Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Completed
2
11
US
Busulfan, Busulfex, Myleran, Fludarabine, Fludarabine Phosphate, Fludara, Clofarabine, Clofarex, Clolar, Total Body Irradiation (TBI), TBI, XRT, Thymoglobulin, ATG (Rabbit), Rabbit Antithymocyte Globulin, Rabbit Antilymphocyte Globulin, Rabbit ATG, rATG, Stem Cell Infusion, Cyclophosphamide, Cytoxan, Neosar, Tacrolimus, Prograf, Mycophenolate mofetil, MMF, CellCept, Decitabine, Dacogen, Cytarabine, Ara-C, Cytosar, DepoCyt, Cytosine Arabinosine Hydrochloride, Idarubicin, Idamycin
M.D. Anderson Cancer Center
Leukemia
09/20
09/21
NCT04816526: Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Terminated
2
13
US
Descartes 08
Cartesian Therapeutics
Myeloma Multiple
08/22
11/22
ADAPT, NCT06028828: Risk-ed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
2
60
US
Fludarabine, Melphalan, Total Body Irradiation, TBI
University of California, Irvine
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Hematologic Malignancies
09/26
09/27
MPCT-012L, NCT05826535: Study of IMPT-314 in R/R Aggressive B-cell NHL

Recruiting
1/2
150
US
IMPT-314
ImmPACT Bio
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
06/25
12/29
NCT05905328: Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

Recruiting
1/2
54
US
CTO1681 10 μg, CTO1681 20 μg, CTO1681 30 μg
CytoAgents, Inc., TFS HealthScience
Cytokine Release Syndrome
06/27
06/27
BMT CTN 1702, NCT03904134: Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation

Active, not recruiting
N/A
1753
US
Donor Search Prognosis Score
Center for International Blood and Marrow Transplant Research, National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Blood and Marrow Transplant Clinical Trials Network, National Marrow Donor Program, Medical College of Wisconsin
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Acquired Aplastic Anemia, Sickle Cell Disease
06/24
03/25
Uchio, Edward
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
ENLIGHTED, NCT04620239 / 2020-004494-41: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer () Study

Recruiting
3
100
Europe, US, RoW
padeliporfin VTP, WST11
Steba Biotech S.A., PrimeVigilance, ICON plc
Transitional Cell Cancer of Renal Pelvis and Ureter
12/24
01/29
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting
1/2
222
Canada, US
EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2
enGene, Inc.
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
06/25
05/27
PRESERVE, NCT04972097: Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

Active, not recruiting
N/A
121
US
Irreversible Electroporation, The NanoKnife System
Angiodynamics, Inc.
Prostate Cancer
07/24
07/24
Hoenigl, Martin
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
2
203
Europe, US, RoW
Olorofim, F901318
F2G Biotech GmbH, Iqvia Pty Ltd
Invasive Fungal Infections
02/23
02/23
Wallace, Daniel
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

Recruiting
4
350
Europe, Japan, US, RoW
Belimumab (GSK1550188), BEL (BENLYSTA)
GlaxoSmithKline
Systemic Lupus Erythematosus
04/27
05/29
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
NCT06104124: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Recruiting
3
621
Europe, Canada, Japan, US, RoW
Dazodalibep, VIB 4920, MEDI 4920, Placebo
Amgen
Sjogren's Syndrome
08/26
08/26
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Recruiting
3
420
Europe, Canada, US, RoW
ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Lupus Nephritis
03/27
07/30
NCT02633163: Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

Recruiting
2
81
US
Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion
Medical University of South Carolina
Systemic Lupus Erythematosus
08/25
02/26
NCT00775476: Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Recruiting
2
290
US
N-acetylcysteine, Placebo
State University of New York - Upstate Medical University, Cedars-Sinai Medical Center, University of Rochester, Yale University, Penn State University, Hospital for Special Surgery, New York, Ohio State University, Oklahoma City VA Health Care System, St. Luke's Hospital and Health Network, Pennsylvania
Systemic Lupus Erythematosus
03/27
09/28
ReLATE, NCT05845593: Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE

Recruiting
N/A
200
US
Decision Support Test
Ampel BioSolutions, LLC
Lupus Erythematosus, Systemic
12/24
03/25
NCT05934149: Lupus Landmark Study: A Prospective Registry and Biorepository

Recruiting
N/A
3500
Canada, US
Lupus Research Alliance
Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
12/33
12/33
Mozaffar, Tahseen
Fortify, NCT05775848: Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Active, not recruiting
3
81
Europe, US, RoW
BBP-418 (ribitol), Placebo
ML Bio Solutions, Inc.
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
07/27
07/27
 

Download Options